Search

everythinglearnresearchcommunity

for

Search:↓

In alopecia areata, certain immune cells increase and express a protein linked to immune activation.

NKG2D+CD4+ T cells are higher in alopecia areata patients and may be involved in the disease.

Expanded CD8+ T cells are linked to Alopecia Areata and may cause relapse after treatment.

BST2 is highly expressed in certain immune cells in alopecia areata, suggesting a role in the disease.

Alopecia areata is an autoimmune condition causing hair loss, linked to genetic factors and immune system issues, with no cure yet.

Down Syndrome patients with Alopecia Areata often have hypothyroidism and specific immune abnormalities.

Patients with RASopathies have a higher risk of autoimmune disorders and should be routinely screened.

Both vitiligo and alopecia areata involve an immune response triggered by stress and specific genes, with treatments targeting this pathway showing potential.

Alefacept showed some effectiveness for alopecia areata but needs more research.

iNKT cells can help prevent and treat alopecia areata by promoting hair regrowth.

ILC1 cells contribute to hair loss in alopecia areata.

RANKL improves the immune response against herpes simplex virus by enhancing T cell activation and could help develop better treatments or vaccines.

Skin bacteria can help wound healing by activating certain immune cells.

Some patients with a type of skin lymphoma can experience a rare, non-scarring hair loss that looks like another hair loss condition but has distinct features.

Genetic mutation and carcinogen treatment are both needed for skin cancer to develop in these specific mice.

Hair follicles may help teach the immune system to tolerate new self-antigens, but this can sometimes cause hair loss.

Scalp biopsies are crucial for diagnosing hair loss causes in cutaneous lymphoma patients.

Autoimmune hair loss may be linked to increased Th1 and Th17 cells and decreased Th2 cells.

A rare type of skin cancer with mucosal involvement was partially treated but eventually relapsed.

Contact immunotherapy can cause vitiligo in patients with autoimmune conditions.

JAK inhibitors and combination therapies show promise for treating severe alopecia areata.

Belimumab may cause hair loss in lupus patients.

Blocking the CXCR3 receptor reduces T cell accumulation in the skin and prevents hair loss in mice.

Topical diphencyprone helped regrow hair in mice and rats with a condition similar to human hair loss.

CD8+ T cells expand significantly in alopecia areata, suggesting new treatment targets.

Skin's Regulatory T cells are crucial for maintaining skin health and could be targeted to treat immune-related skin diseases and cancer.

Animal models have helped understand hair loss from alopecia areata and find new treatments.

CD8+ T cells are involved in alopecia areata and may cause disease relapse.

EGCG may help treat alopecia areata by blocking certain immune responses and reducing specific harmful immune cells.

Deucravacitinib improves symptoms and reduces inflammation in Lichen Planopilaris.